CDX-585

About celldex-therapeutics

Celldex Therapeutics is a disciplined, R&D-focused biotech with a 40-year legacy, strategically pivoted to become a leader in developing targeted antibody therapeutics for immunology and oncology. Its most advanced asset, barzolvolimab, a mast cell-depleting KIT inhibitor, has demonstrated compelling late-stage data in chronic urticaria and is advancing in multiple inflammatory indications, positioning the company for near-term commercialization. Celldex's strategy leverages proprietary antibody platforms and in-house capabilities to build a diversified pipeline aimed at addressing root causes of disease beyond symptomatic management.

Therapeutic Areas